Health · Public Health & Disease · 8 hrs ago
Reanalysis puts first-year benefits of COVID-19 vaccines at up to $64.3 trillion
A reanalysis estimates that COVID-19 vaccines brought up to $64.3 trillion in benefits during their first year of rollout.
Earlier estimates put the global benefits at up to $37.9 trillion, based on research that had not yet been peer-reviewed.
The updated figures range from $6.43 trillion to $64.3 trillion, depending on how benefits are valued.
The analysis covers 173 countries and counts lives saved, hospitalisations avoided and reduced losses in productivity.
Researchers estimated that vaccine development received $79.4 billion in investment, and that returns were highest in richer countries, where vaccines were accessed earlier.
The uneven returns highlight the importance of fair vaccine distribution, particularly to people in poorer countries.
Researchers say the findings could inform responses to future pandemics and disease outbreaks.
A reanalysis estimates that COVID-19 vaccines delivered up to $64.3 trillion in global health and economic benefits during their first year.
That is higher than the earlier estimate of up to $37.9 trillion.
The revised range is $6.43 trillion to $64.3 trillion, depending on the method used.
The analysis includes data from 173 countries on hospitalisations, productivity losses and lives saved.
The researchers found that returns were highest in richer countries, in part because poorer countries received vaccines later.
- Who
- Researchers reanalysed the benefits of COVID-19 vaccines; Hallie Benjamin and Mark Jit commented on the findings.
- What
- A reanalysis estimates first-year global benefits of $6.43 trillion to $64.3 trillion.
- When
- The estimates cover the first 12 months after the vaccines’ rollout. The article was published on 2026-11-05.
- Where
- The analysis includes data from 173 countries.
- Why
- The researchers revised their estimates during peer review, including changing how they valued deaths averted.
This story does not have two clearly opposing sides.
The original analysis estimated global returns of $4.8 trillion to $37.9 trillion from $79.4 billion invested in vaccine development.
The researchers changed how they valued mortality-risk reductions and made other changes to strengthen the findings.
New Scientist reported the reanalysis, which estimated returns of $6.43 trillion to $64.3 trillion.
- Revised benefit range
- $6.43 trillion to $64.3 trillion
- Earlier benefit range
- $4.8 trillion to $37.9 trillion
- Vaccine development investment
- $79.4 billion
- Countries included
- 173
- Estimated deaths prevented
- 14 million to 20 million in the first year
What people are saying
It is great to finally see this research published to demonstrate the enormous health and financial benefits gained from covid-19 vaccines, in comparison to the costs that went into their development and delivery
The results are a message about the need for being able to distribute the vaccines fairly to the people most in need around the world
protecting the public’s health is protecting the economy